City

Bebington (1)

Liverpool (1)

Minneapolis (1)

New York (1)

Roma (1)

Tampa (1)

Tucson (1)

Overall Status

Completed (3)

Recruiting (1)

Phase

phase 1 (3)

phase 1/phase 2 (1)

Sponsor

Epizyme, Inc. (2)

Bambino Gesu Hospital and Research Institute (1)

Masonic Cancer Center, University of Minnesota (1)

Collaborator

Intervention

cd19-car_lenti t cell (1)

fluconazole (1)

nicotinamide expanded haploidentical or mismatched related donor natural killer cells (1)

omeprazole (1)

repaglinide (1)

tazemetostat (1)

tazemetostat and [14c] tazemetostat (1)

Study Documents

Intervention Type

biological (2)

drug (2)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

primary mediastinal lymphoma

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed

Multiple Myeloma
+7 more

Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Minneapolis, Minnesota

Masonic Cancer Center, University of Minnesota

Nov 2, 2022

Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma Trial in Tucson, Tampa, New York

Completed

Has Results

Diffuse Large B Cell Lymphoma
+4 more

Tazemetostat
+3 more

Tucson, Arizona
+2 more

Mar 23, 2021

Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma Trial in Roma (CD19-CAR_Lenti T cell)

Recruiting

Acute Lymphoblastic Leukemia
+2 more

CD19-CAR_Lenti T cell

Roma, Italy

IRCCS Ospedale Pediatrico Bambino Gesù

Mar 24, 2021

Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma Trial in Bebington, Liverpool (Tazemetostat

Completed

Diffuse Large B Cell Lymphoma
+5 more

Tazemetostat and [14C] Tazemetostat

Bebington, Wirral, United Kingdom
+1 more

Jan 8, 2020